TG Therapeutics TGTX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Vor BiopharmaVOR

$2.94M-90.5%

Mirum Pharmaceuticals, Inc.MIRM

$12.87M+29.2%

BridgeBio PharmaBBIO

$18.66M+84.3%

Neurocrine BiosciencesNBIX

$463.5M-6.0%

Zevra Therapeutics, Inc.ZVRA

$1.5M-5.6%

Acadia PharmaceuticalsACAD

$73.85M+31.2%

FAQ

What is TG Therapeutics's operating lease liabilities (total)?

TG Therapeutics (TGTX) reported operating lease liabilities (total) of $9.05M in Q2 2026.

How has TG Therapeutics's operating lease liabilities (total) changed year-over-year?

TG Therapeutics's operating lease liabilities (total) increased by 4.3% year-over-year, from $8.68M to $9.05M.

What is the long-term trend for TG Therapeutics's operating lease liabilities (total)?

Over 5 years (2020 to 2025), TG Therapeutics's operating lease liabilities (total) has grown at a -7.8% compound annual growth rate (CAGR), from $12.08M to $8.07M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.